Advocacy Wealth Management LLC Lowers Position in Stryker Corporation $SYK

Advocacy Wealth Management LLC lessened its stake in Stryker Corporation (NYSE:SYK) by 6.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 38,586 shares of the medical technology company’s stock after selling 2,449 shares during the quarter. Advocacy Wealth Management LLC’s holdings in Stryker were worth $13,562,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker in the 4th quarter worth $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker in the third quarter valued at $27,000. CGC Financial Services LLC purchased a new stake in shares of Stryker in the fourth quarter valued at $29,000. Strive Asset Management LLC purchased a new stake in shares of Stryker in the third quarter valued at $30,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in shares of Stryker in the third quarter valued at $34,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,264 shares of company stock valued at $100,659,489 in the last three months. 4.60% of the stock is owned by insiders.

Stryker Stock Performance

SYK stock opened at $301.75 on Tuesday. The firm has a market cap of $115.68 billion, a price-to-earnings ratio of 34.92, a PEG ratio of 1.93 and a beta of 0.78. The firm has a 50-day simple moving average of $317.81 and a two-hundred day simple moving average of $345.36. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Evercore set a $355.00 price objective on shares of Stryker in a research report on Friday, May 1st. Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. BTIG Research lowered their target price on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Finally, Leerink Partners cut their price target on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.